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Abstract
Background: Hepatitis B e antigen (HBeAg) seroclearance has been considered as the treatment endpoint in
HBeAg-positive patients with chronic hepatitis B (CHB). Although HBeAg seroclearance has been accomplished,
some aspects are yet unclear. We investigated the cumulative incidence of hepatocellular carcinoma (HCC) and
evaluated hepatitis B surface antigen (HBsAg) seroclearance in patients undergoing nucleos(t) ide analogue (NA)-
induced HBeAg seroclearance.
Methods: In this retrospective cohort study, 203 patients with CHB were HBsAg and HBeAg seropositive before NA
(entecavir or tenofovir) treatment. All patient who experienced NA -induced HBeAg seroclearance were recruited.
Patients with documented HBeAg seroclearance were followed-up every 6 months. Baseline characteristics and
laboratory results were recorded.
Results: The mean age at HBeAg seroclearance was 40 years (range, 20–84), and the mean follow-up duration was
5 years (range, 2–11). The cumulative incidence of HCC was 1.5 to 11.5% at 1 to 8 years after HBeAg seroclearance.
Cirrhosis was the only significant factor for HCC development (hazard ratio [HR], 24.651; confidence interval [CI],
3.018 to 201.365; P = 0.003). The cumulative incidence of HBsAg seroclearance was 3.5 to 18.7% after 1 to 8 years
from HBeAg seroclearance.
Conclusions: A significant proportion of patients developed HCC after NA-induced HBeAg seroclearance. The
presence of liver cirrhosis at the time of HBeAg seroclearance serves as an independent factor for HCC
development. Some patients with NA-induced HBeAg seroclearance achieved HBsAg seroclearance.
Keywords: Hepatitis B virus, Hepatitis B e antigen seroclearance, Hepatitis B s antigen seroclearance, Hepatocellular
carcinoma
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Background
Nucleos(t) ide analogues (NAs) are commonly used in pa-
tients with chronic hepatitis B (CHB). Recent drugs show
high efficacy, less side-effects, and rare antiviral resistance.
Currently ultimate treatment endpoint is virologic cure char-
acterized with the eradication of virus, including the cova-
lently closed circular DNA (cccDNA) form [1–3]. However,
such an endpoint is rarely achieved with current antiviral
agents. As a potentially achievable step, hepatitis B e antigen
(HBeAg) seroclearance has been considered as the real thera-
peutic goal in HBeAg-positive patients with CHB. Although
evidence is insufficient and recommendations are few, NAs
may be discontinued in HBeAg-positive patients with CHB
that achieved HBeAg seroconversion and opted consolida-
tion therapy for more than 12months [2–4]. In particular, it
is still considered as an antiviral termination rule by regional
treatment guidelines because life-long antiviral therapy is not
covered with medical reimbursement system [5].
As an alternative, hepatitis B s antigen (HBsAg) sero-
clearance has been termed as functional cure [1–3]. It is
different from true cure, wherein the cccDNA is elimi-
nated. It is similar to the natural condition known as oc-
cult HBV infection or an equivalent to resolved acute
hepatitis B. Spontaneous, NA-induced or interferon-
induced HBsAg seroclearance has been reported to occur
at a rate of 1–2, 1–2% or 2%–7%, respectively [6–9]. In
other words, it is difficult to achieve this goal with current
antiviral agents.
Although HBeAg or HBsAg seroclearance has been ac-
complished, some aspects are yet unclear [10]. This ac-
complishment showed favorable outcomes such as
decreased incidence of hepatocellular carcinoma (HCC)
and decompensated liver cirrhosis and transplantation
[11, 12]. However, a significant proportion of patients may
experience HCC after HBeAg or even HBsAg seroclear-
ance. Therefore, here we investigated the cumulative inci-
dence of HCC and evaluated HBsAg seroclearance in
patients undergoing NA-induced HBeAg seroclearance.
Methods
Patients and data collection
This is a retrospective cohort study using data from a ter-
tiary hospital. Between January 2006 and December 2016,
1256 CHB patients with HBeAg positive were treated with
NA (entecavir or tenofovir) as a first line or rescue ther-
apy. Among them, 203 patients (16.2) experienced NA-
induced HBeAg seroclearance. They were all recruited
from the Gangnam Severance hospital, Yonsei University
College of Medicine, Korea. We included patients aged 18
years or above that were HBsAg- and HBeAg-positive for
at least 6months. The enrolled subjects took antiviral
therapy and experienced HBeAg seroclearance. We ex-
cluded patients that experienced peginterferon treatment.
We excluded patients that were co-infected with hepatitis
C virus or human immunodeficiency virus. Patients with
other concomitant chronic liver diseases (e.g., alcoholic
liver disease and autoimmune hepatitis) and evidence of
decompensated liver cirrhosis and HCC using ultrasonog-
raphy and computerized tomography were also excluded.
Clinical outcomes, including development of HCC and
HBsAg seroclearance, were recorded.
Data from 18 patients who were lost to follow up
without HBsAg seroclearance were censored at the last
available observation for the cumulative incidence of
HBsAg seroclearance, and HCC. However, 16 patients
who achieved HBsAg seroclearance were followed up
regularly until the last observation period.
The study protocol was performed in accordance with
the ethics guidelines of the 1975 Declaration of Helsinki,
and the study was approved by the Institutional Review
Board of Gangnam Severance Hospital. As this study was
a retrospective design, written consent was not required.
Patient monitoring
Patients with CHB were followed up at a regular interval
of 6 months. Patients were subjected to routine liver bio-
chemistry, HBV serology, and ultrasonography tests. Cir-
rhosis was clinically defined based on ultrasonographical
features, including small-sized liver, nodular surface, and
splenomegaly (> 12 cm) with or without the manifesta-
tions of portal hypertension. The diagnosis of decom-
pensated liver cirrhosis was based on clinical
presentations such as variceal bleeding or hepatic en-
cephalopathy and radiological presence of ascites.
Viral load
Serum HBV DNA levels were quantified using a com-
mercially available real-time polymerase chain reaction
assay (COBAS AmpliPrep-COBAS TaqMan HBV test,
detection limit = 12 IU/mL; Roche Diagnostics, Basel,
Switzerland). Measurements of HBV DNA were rou-
tinely performed at every 6 months.
Antiviral therapy
Antiviral therapy was decided based on the Korean Associ-
ation for the Study of the Liver clinical practice guidelines
for the management of CHB [3, 13]. All except 12 patients
were continued on antiviral therapy after HBeAg seroclear-
ance to achieve HBsAg seroclearance. Just 12 patients were
discontinued antiviral treatment after consolidation therapy
for more than 12months after HBeAg seroclearance.
Primary endpoint
The primary endpoint of our study comprised the inci-
dence of HCC and HBsAg seroclearance. HCC diagnosis
was carried out using either histopathology or imaging
based on the guidelines of the European Association for
the Study of the Liver or the American Association for
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the Study of Liver Disease [14, 15]. Briefly, HCC was di-
agnosed based on the typical findings of dynamic com-
puted tomography or magnetic resonance imaging
(hypervascularity in the arterial phase with delayed phase
washout). If the criteria were not met, HCC was con-
firmed with liver biopsy. HBsAg seroclearance was de-
fined as at least two negative HBsAg test results, with
the last HBsAg test being negative in CHB patients with
HBeAg seroclearance during antiviral therapy.
Statistical analysis
Baseline characteristics were described as number (%) and
mean with standard deviation. Student’s t-test was used to
compare mean age at HBeAg seroclearance among each
group. Chi-square test or Fisher’s exact test was used to
compare the sex ratio, the presence of liver cirrhosis,
detectable HBV DNA, and elevated ALT at HBeAg sero-
celarance and the type of antiviral agents. The Mann-
Whitney U test was used for comparing two continuous
variables with skewed distribution. Kaplan-Meier curves
were constructed to examine cumulative incidences of
HCC and HBsAg seroclearance. The variables that were
significant in the univariate analysis were selected to de-
velop a multivariate Cox proportional hazard model for
the identification of independent predictors of HCC devel-
opment and HBsAg seroclearance. The cumulative rate of
HCC development, and HBsAg seroclearance were esti-
mated using the Kaplan-Meier method and p values were
calculated using the log-rank test, according to age at
HBeAg seroclearance, male gender and cirrhosis, etc. Stat-
istical analysis was performed using SPSS version 25.0
(IBM Co., Armonk, NY, USA). A value of P < 0.05 was
considered statistically significant.
Results
Patient characteristics at baseline
This cohort of 203 patients with CHB showing NA-
induced HBeAg seroclearance was followed-up for up to
8 years. The mean age was 37 years (range, 18–82) at
baseline and 40 years (range, 20–84) at the time of
HBeAg seroclearance. The mean follow-up duration was
5 years (range, 2–11). Baseline characteristics of patients
are shown in Table 1. All patients received oral antiviral
therapy before HBeAg seroclearance. A total of 173
(85.2%) patients received entecavir or tenofovir as the
first-line treatment. The remaining 30 (14.8%) patients
received tenofovir only or tenofovir plus entecavir com-
bination therapy as a rescue therapy. One hundred
seventy-five (86.2%) patients had normal alanine amino-
transferase (ALT) levels at the time of HBeAg seroclear-
ance, while 28 (13.8%) had abnormal ALT levels (range,
41–110 IU/L). One hundred fifty-two (74.9%) patients
showed undetectable HBV DNA (< 12 IU/mL) at the
time of HBeAg seroclearance, while 51 (25.1%) had sus-
tained detectable HBV DNA (range, 1.3–4.9 IU/mL).
Cumulative incidence of HCC
A total of 16 (7.9%) patients developed HCC during a
mean follow-up period of 5 years (range, 2–11). The cu-
mulative incidence of HCC was 1.5, 6.2, 10.0, and 11.5% at
1, 3, 5, and 8 years after HBeAg seroclearance, respectively
(Fig. 1a). According to the presence of cirrhosis, the cu-
mulative incidence of HCC ranged from 4% at 1 year to
28.0% at 8 years after HBeAg seroclearance and was sig-
nificantly higher in patients with cirrhosis than in those
without cirrhosis (P < 0.001) (Fig. 1b). In patients that
achieved HBeAg seroclearance before 30, 31–40, 41–50,
and > 50 years of age, the cumulative incidence of HCC
was 0, 5.2, 14.1, and 34.3%, respectively, after 8 years from
HBeAg seroclearance (P = 0.001; Fig. 1c). The mean age
for HCC development was 52 years (range, 43–75).
Based on the ALT level at the time of HBeAg sero-
clearance, no significant difference was observed in
the incidence of HCC between elevated ALT and nor-
mal ALT groups (10.1% versus 11.8%, P = 0.784). In
addition, HBV DNA level analysis at the time of
HBeAg seroclearance revealed no significant differ-
ence in the incidence of HCC between sustained de-
tectable HBV DNA and undetectable HBV DNA
groups (13.3% versus 8.3%, P = 0.821).
Table 1 Clinical characteristics of 203 patients with chronic
hepatitis B with nucleos(t) ide analogue-induced HBeAg
seroclearance
Variables Values
Cohort number (n) 203
Male: Female (%) 128:75 (63.1:36.9)
Mean age at baseline, year (range) 37 (18–82)
Mean age at HBeAg seroclearance, year (range) 40 (20–84)
Mean age at last follow-up, year (range) 44 (24–85)
Follow-up duration, year (range) 5 (2–11)
First-line antiviral therapy (%) 173 (85.2)
Entecavir: Tenofovir: Entecavir plus Tenofovir (%) 152:49:2 (74.9:24.1:1.0)
At time of HBeAg seroclearance
Liver cirrhosis (%) 75 (36.9)
Diabetes (%) 33 (16.3)
Mean HBV DNA†, log10 IU/mL (range) 1.3 (negative-4.9)
Mean ALT*, IU/L (range) 25 (14–110)
Mean albumin, g/dL (range) 4.2 (3.0–5.1)
Mean bilirubin, mg/dL (range) 1.0 (0.8–2.5)
Mean platelet count, 103/μL (range) 183 (130–427)
NOTE. Values are given as mean (range)
*The upper limit of normal ALT level is less than 40 IU/L.
†The lower limit of detection for HBV DNA is 12 IU/mL
Abbreviations: ALT alanine aminotransferase; HBV hepatitis B virus
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Fig. 1 (See legend on next page.)
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In the multivariate Cox proportional hazard analysis,
age, male gender, cirrhosis, detectable HBV DNA, ele-
vated ALT, and type of antiviral agent (entecavir and
tenofovir) at the time of HBeAg seroclearance were in-
cluded. The presence of cirrhosis was the only signifi-
cant factor associated with HCC development (hazard
ratio [HR], 24.651; confidence interval [CI], 3.018 to
201.365; P = 0.003) (Table 2).
Cumulative incidence of HBsAg seroclearance
A total of 16 patients achieved HBsAg seroclearance,
and 13 of these patients achieved HBsAg seroconversion
with anti-HBs. The cumulative incidence of HBsAg sero-
clearance was 3.5, 4.7, 10.2, and 18.7% at 1, 3, 5, and 8
years after HBeAg seroclearance, respectively (Fig. 2a).
For patients that achieved HBeAg seroclearance before
the age of 30, 31–40, 41–50, and > 50 years, the cumula-
tive rate of HBsAg seroclearance was 0, 5.1, 41.7, and
22.9%, respectively, after 8 years from HBeAg seroclear-
ance (P = 0.005; Fig. 2B). The mean age at HBsAg sero-
clearance was 48 years (range, 35–70).
As per the ALT level at the time of HBeAg seroclear-
ance, no significant difference was reported in the inci-
dence of HBsAg seroclearance between elevated ALT
and normal ALT groups (14.3% versus 21.1%, P = 0.448).
The HBV DNA level at the time of HBeAg seroclearance
also revealed the absence of any significant difference in
the incidence of HBsAg seroclearance between sustained
detectable HBV DNA and undetectable HBV DNA
groups (15.6% versus 17.6%, P = 0.834).
In addition, no significant difference was observed in
the cumulative incidence of HCC between HBsAg sero-
clearance and sustained HBsAg-positive groups (22.5%
versus 10.5%, P = 0.069; Fig. 3).
In the multivariate Cox proportional hazard analysis,
age, male gender, cirrhosis, detectable HBV DNA, ele-
vated ALT, and type of antiviral agent (entecavir and
tenofovir) at the time of HBeAg seroclearance were in-
cluded, and no factor was found to be significantly re-
lated to HBsAg seroclearance (Table 2).
Discussion
A significantly high incidence of HCC was observed in
patients with liver cirrhosis during the time of HBeAg
seroclearance. This observation highlights the import-
ance of liver cirrhosis in patients during antiviral ther-
apy. Among 16 patients with HCC, only one male
patient developed HCC without cirrhosis. He was 49
(See figure on previous page.)
Fig. 1 Cumulative incidence of hepatocellular carcinoma (a) according to the presence of cirrhosis (b) and age at the time of HBeAg
seroclearance (c). The cumulative incidence of HCC was 1.5, 6.2, 10.0, and 11.5% at 1, 3, 5, and 8 years after HBeAg seroclearance, respectively (a).
It was significantly higher in patients with cirrhosis than in those without cirrhosis (b). For patients that achieved HBeAg seroclearance before 30,
31–40, 41–50, and > 50 years of age, the cumulative incidence of HCC was 0, 5.2, 14.1, and 34.3%, respectively, at 8 years after HBeAg
seroclearance (c). HCC, hepatocellular carcinoma. P values were determined using log-rank testing
Table 2 Multivariate analyses for the factors associated with hepatocellular carcinoma and HBsAg seroclearance
Variables Adjusted HR 95% CI P-value*
Development of HCC
Age at HBeAg seroclearance 1.045 0.990–1.103 0.111
Male gender 2.986 0.777–11.472 0.111
Cirrhosis 24.651 3.0128–201.365 0.017
Detectable HBV DNA† at HBeAg seroclearance 1.228 0.295–5.108 0.778
Elevated ALT‡ at HBeAg seroclearance 1.625 0.268–9.864 0.598
Tenofovir (versus entecavir) 0.868 0.233–3.237 0.833
Achievement of HBsAg seroclearance
Age at HBeAg seroclearance 1.037 0.995–1.082 0.086
Male gender 0.886 0.306–2.568 0.824
Cirrhosis 1.042 0.351–3.094 0.941
Detectable HBV DNA† at HBeAg seroclearance 0.980 0.264–3.639 0.976
Elevated ALT‡ at HBeAg seroclearance 2.169 0.501–9.397 0.301
Tenofovir (versus entecavir) 1.388 0.461–4.178 0.560
*P-value from logistic regression models
†The lower limit of detection for HBV DNA is 12 IU/mL
‡The upper limit of normal ALT level is less than 40 IU/L.
Abbreviations: HR hazard ratio; CI, confidence interval; HCC hepatocellular carcinoma; ALT alanine aminotransferase; HBV hepatitis B virus; HBeAg Hepatitis B e
antigen; HBsAg Hepatitis B s antigen
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years at the time of HBeAg seroclearance and did not
experience HBsAg seroclearance. HCC was mostly de-
veloped in patients with cirrhosis.
Considering the effectiveness of antiviral therapy (ente-
cavir, tenofovir, or combination therapy), the majority of
patients showed undetectable HBV DNA (n = 152/203,
74.9%) and normal ALT levels (n = 175/203, 86.2%). Ac-
cording to previous reports, patients with CHB exhibiting
sustained normal ALT level and undetectable HBV DNA
level could have a more favorable outcome with lower
Fig. 2 Cumulative incidence of HBsAg seroclearance (a) according to age during HBeAg seroclearance (b). The cumulative incidence of HBsAg
seroclearance was 3.5, 4.7, 10.2, and 18.7% at 1, 3, 5, and 8 years after HBeAg seroclearance, respectively (a). For patients that achieved HBeAg
seroclearance before 30, 31–40, 41–50, and > 50 years of age, the cumulative rate of HBsAg seroclearance was 0, 5.1, 41.7, and 22.9%, respectively,
at 8 years after HBeAg seroclearance (b). P values were determined using log-rank testing
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incidence of HCC than those with fluctuated HBV DNA
or elevated ALT levels [16–18]. However, in our cohort,
patients with undetectable HBV DNA at the time of
HBeAg seroclearance demonstrated sustained suppression
of HBV DNA (n = 137/152, 85.5%). Among patients with
normal ALT at the time of HBeAg seroclearance, only a
small proportion (n = 23/175, 13.1%) showed fluctuated
ALT elevation. Patients who showed fluctuated ALT level
had other concomitant diseases such as diabetes and fatty
liver. Therefore, detectable HBV DNA and elevated ALT
were not important factors for the development of HCC
during antiviral therapy.
In previous reports, age above 50 years and male gen-
der were the two independent risk factors for HCC after
HBsAg seroclearance [19]. In our study, among 16 pa-
tients with HBsAg seroclearance, only three developed
HCC. These three patients had cirrhosis and included
two males (59 and 56 years) and one female (53 years).
Similar to a previous report, patients with age above 50
years or male gender experienced HCC development
after HBsAg seroclearance. However, in terms of HBsAg
seroclearance, no statistically significant difference was
observed in the development of HCC between HBsAg
seroclearance and HBsAg-positive groups after HBeAg
seroclearance (P = 0.069, Fig. 3).
We found that the cumulative incidence of HCC ac-
cording to age at the time of HBeAg seroclearance was
higher in patients above 40 years of age than in younger
patients (P = 0.001, Fig. 1c). However, multivariate analysis
results showed that only the presence of cirrhosis was a
significant independent predictor for HCC development.
Even though NA induced HBeAg seroclearance, a signifi-
cant proportion of patients with liver cirrhosis experi-
enced HCC. As HBeAg seroclearance means effective
antiviral response in HBeAg-positive CHB patients, HCC
surveillance could be overlooked. Therefore, HCC surveil-
lance every 6 months is warranted even after NA-induced
HBeAg seroclearance in patients with liver cirrhosis.
The cumulative incidence of HBsAg seroclearance was
18.7% after 8 years of HBeAg seroclearance. Male gender
was not an important factor associated with HBsAg ser-
oclearance (male versus female, 10/128 versus 6/75; P =
Fig. 3 Cumulative incidence of hepatocellular carcinoma based on the achievement of HBsAg seroclearance. No significant difference was
observed in the cumulative incidence of HCC between HBsAg seroclearance and sustained HBsAg-positive groups. HCC, hepatocellular
carcinoma. P values were determined using log-rank testing
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0.962). A significantly increase in the incidence of
HBsAg seroclearance was observed in patients above 40
years of age at the time of HBeAg seroclearance (P =
0.005, Fig. 2b). This observation suggests that HBsAg
seroclearance may require not only the efficacy of potent
antiviral agents but also unknown host immune re-
sponse related to age. However, the results of multivari-
ate analysis revealed no significant independent
predictor related to HBsAg seroclearance. Thus, life-
long antiviral therapy is needed to achieve functional
cure even after achieving HBeAg seroclearance.
Choi et al. recently reported the association between
tenofovir treatment and significantly lower risk of HCC
as compared with entecavir treatment in a population-
based cohort study [20]. In our study, all patients were
treated with entecavir (n = 152), tenofovir (n = 49), or
combination of both (n = 2) as the first line or rescue
therapy. Although the number of patients was small, the
type of antiviral agent was not related to HCC develop-
ment and achievement of HBsAg seroclearance.
The present study has several limitations. First, this is
a retrospective cohort study with small sample size from
one tertiary hospital. Second, we observed disparities in
follow-up periods between HBsAg seroclearance group
and sustained HBsAg-positive group, owing to the vol-
untary follow-up loss after achieving HBeAg seroconver-
sion. Third, the HBV genotype and mutation profile
analyses were not routinely performed. However, the
genotype C2 was predominant in more than 98% Korean
patients with CHB [21]. In addition, among 30 patients
that underwent rescue therapy, 28 had undetectable
HBV DNA regardless of lamivudine or adefovir mutant
profiles. There was no difference in outcomes in patients
who had NAs as first line or rescue therapy.
Conclusions
A significant proportion of patients developed HCC after
NA-induced HBeAg seroclearance. The presence of liver
cirrhosis at the time of HBeAg seroclearance is an inde-
pendent factor for HCC development. Some patients
with NA-induced HBeAg seroclearance experienced
HBsAg seroclearance. Therefore, HCC surveillance every
6 months is advocated for HCC detection at early tumor
stages, and antiviral therapy must be continued to
achieve functional cure even after achieving HBeAg ser-
oclearance in HBeAg-positive patients with CHB.
Abbreviations
ALT: Alanine aminotransferase; cccDNA: Covalently closed circular DNA;
CHB: Chronic hepatitis B; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen;





HWL and KSL have full access to all data in the study and take the
responsibility of data integrity and accuracy of analysis. All Authors read and
approved the manuscript. Study concept and design: HWL and KSL.
Acquisition of data: SIK, SRK, and HYC. Analysis and interpretation of data: JIL
and KSL. Drafting of the manuscript: HWL. Statistical analysis: JIL and HWL.
Funding
This study was supported by a faculty research grant of Yonsei University
College of Medicine (6–2019-0091). The leader of these fundings play a role
in the design of the study, collection, analysis, interpretation of the data, and
in writing the manuscript, and these fundings provide fund for this study.
Availability of data and materials
The data used and/or analyzed during the study are available from the
corresponding author on reasonable request.
Ethics approval and consent to participate
This study was approved by the Institutional Review Board of Gangnam





Hyun Woong Lee is a member of the editorial board of BMC
gastroenterology.
The other authors declare that they have no competing interests.
Received: 13 October 2019 Accepted: 25 March 2020
References
1. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis,
and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Clin
Liver Dis (Hoboken). 2018;12:33–4.
2. European Association for the Study of the Liver. Electronic address eee,
European Association for the Study of the L. EASL 2017 Clinical Practice
Guidelines on the management of hepatitis B virus infection. J Hepatol.
2017;67:370–98.
3. Korean Association for the Study of the L. KASL clinical practice guidelines
for management of chronic hepatitis B. Clin Mol Hepatol. 2019;25:93–159.
4. Lee HW, Lee HJ, Hwang JS, et al. Lamivudine maintenance beyond one year
after HBeAg seroconversion is a major factor for sustained virologic
response in HBeAg-positive chronic hepatitis B. Hepatology. 2010;51:415–21.
5. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on
the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.
6. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high
endemic areas: appreciably high rates during a long-term follow-up.
Hepatology. 2007;45:1187–92.
7. Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous
hepatitis B surface antigen seroclearance: a community-based follow-up
study. Gastroenterology. 2010;139:474–82.
8. Yip TC, Wong GL, Wong VW, et al. Durability of hepatitis B surface antigen
seroclearance in untreated and nucleos(t) ide analogue-treated patients. J
Hepatol. 2017.
9. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after
long-term follow-up of HBeAg-positive patients treated with peginterferon
alpha-2b. Gastroenterology. 2008;135:459–67.
10. Liang LY, Wong GL. Unmet need in chronic hepatitis B management. Clin
Mol Hepatol. 2019;25:172–80.
11. Kim GA, Lim YS, An J, et al. HBsAg seroclearance after nucleoside analogue
therapy in patients with chronic hepatitis B: clinical outcomes and
durability. Gut. 2014;63:1325–32.
12. Chen YC, Sheen IS, Chu CM, et al. Prognosis following spontaneous HBsAg
seroclearance in chronic hepatitis B patients with or without concurrent
infection. Gastroenterology. 2002;123:1084–9.
13. Cho EJ, Kim SE, Suk KT, et al. Current status and strategies for hepatitis B
control in Korea. Clin Mol Hepatol. 2017;23:205–11.
Lee et al. BMC Gastroenterology          (2020) 20:113 Page 8 of 9
14. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and Management of
Hepatocellular Carcinoma: 2018 practice guidance by the American
Association for the Study of Liver Diseases. Hepatology. 2018;68:723–50.
15. European Association for the Study of the Liver. Electronic address eee,
European Association for the Study of the L. EASL Clinical Practice Guidelines:
Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
16. Fung J, Cheung KS, Wong DK, et al. Long-term outcomes and predictive scores
for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after
hepatitis B e-antigen seroclearance. Hepatology. 2018;68:462–72.
17. Yuen MF, Ahn SH, Chen DS, et al. Chronic hepatitis B virus infection: disease
revisit and management recommendations. J Clin Gastroenterol. 2016;50:286–94.
18. Yeo YH, Ho HJ, Yang HI, et al. Factors associated with rates of HBsAg
Seroclearance in adults with chronic HBV infection: a systematic review and
meta-analysis. Gastroenterology. 2019;156:635–46 e639.
19. Yip TC, Chan HL, Wong VW, et al. Impact of age and gender on risk of
hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J
Hepatol. 2017;67:902–8.
20. Choi J, Kim HJ, Lee J, et al. Risk of hepatocellular carcinoma in patients
treated with Entecavir vs Tenofovir for chronic hepatitis B: a Korean
Nationwide cohort study. JAMA Oncol. 2019;5:30–6.
21. Bae SH, Yoon SK, Jang JW, et al. Hepatitis B virus genotype C prevails among
chronic carriers of the virus in Korea. J Korean Med Sci. 2005;20:816–20.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Lee et al. BMC Gastroenterology          (2020) 20:113 Page 9 of 9
